Valuation: Beta Bionics, Inc.

Market Cap 1.08B 950M 898M 815M 1.53B 104B 1.54B 10.76B 4.15B 52.91B 4.06B 3.97B 170B P/E 2026 *
-9.98x
P/E 2027 * -9.39x
Enterprise Value 933M 821M 776M 704M 1.32B 89.6B 1.33B 9.3B 3.59B 45.72B 3.5B 3.43B 147B EV / Sales 2026 *
7.41x
EV / Sales 2027 * 5.68x
Free-Float
99.18%
Yield 2026 *
-
Yield 2027 * -
1 day-4.60%
1 week-6.90%
Current month+2.86%
1 month+4.06%
3 months+22.00%
6 months+90.71%
Current year-32.66%
1 week 19.93
Extreme 19.93
23.48
1 month 15.51
Extreme 15.51
23.56
Current year 8.8
Extreme 8.8
32.58
1 year 8.8
Extreme 8.8
32.71
3 years 8.8
Extreme 8.8
32.71
5 years 8.8
Extreme 8.8
32.71
10 years 8.8
Extreme 8.8
32.71
Manager TitleAgeSince
Chief Executive Officer 50 2022-08-14
Director of Finance/CFO 37 2022-07-31
Chief Tech/Sci/R&D Officer - -
Director TitleAgeSince
Director/Board Member 57 2020-01-31
Director/Board Member 50 2022-08-14
Director/Board Member 63 2024-09-30
Date Insider Type Main position Quantity % Market Cap. Importance
9/22/26 Sell

Director

-6,430 0.0143%
9/16/26 Sell

Executive/Senior Manager

-30,779 0.0684%
9/16/26 Sell

Executive/Senior Manager

-2,650 0.0059%
Change 5-day change 1-year change 3-year change Capi.($)
-4.60%-6.90%+5.07% - 1.13B
+0.53%+3.01%+46.17%+34.91% 250B
+1.27%+5.32%+22.99%-8.03% 158B
+2.37%+3.27%-5.97%+40.06% 143B
+0.43%+0.89%-55.07%-17.35% 63.65B
+0.63%-1.71%+13.88%+24.11% 49.74B
+1.40%+8.19%+42.00%+56.44% 48.71B
+2.33%+1.84%-14.54%-19.90% 47.94B
+2.17%+4.49%+51.84%+60.86% 42.59B
+0.70%+13.85%+196.54%+105.44% 40.77B
Average +0.57%+3.07%+30.29%+30.73% 84.51B
Weighted average by Cap. +0.93%+3.93%+27.29%+26.02%

Financials

2026 *2027 *
Net sales 126M 111M 105M 95.09M 179M 12.1B 180M 1.26B 485M 6.17B 473M 463M 19.84B 182M 160M 151M 137M 258M 17.49B 260M 1.81B 701M 8.92B 684M 669M 28.67B
Net income -93.69M -82.4M -77.92M -70.68M -133M -8.99B -134M -933M -360M -4.59B -352M -344M -14.75B -104M -91.76M -86.77M -78.7M -148M -10.01B -149M -1.04B -401M -5.11B -392M -383M -16.42B
Net Debt -147M -129M -122M -111M -208M -14.09B -209M -1.46B -564M -7.19B -551M -539M -23.1B -46.25M -40.68M -38.47M -34.89M -65.53M -4.44B -65.91M -461M -178M -2.27B -174M -170M -7.28B
Logo Beta Bionics, Inc.
Beta Bionics, Inc. is a commercial-stage medical device company engaged in the design, development and commercialization of various solutions to improve the health of insulin-requiring people with diabetes (PWD). The Company's product, the iLet Bionic Pancreas (iLet), is an insulin delivery device cleared by the United States Food and Drug Administration (FDA) to utilize adaptive closed-loop algorithms to autonomously determine every insulin dose without requiring a user to count carbohydrate intake. iLet is used for the treatment of Type 1 diabetes (T1D). The Company's solutions include iLet for Adults, iLet for Children, Bionic Circle App and iLet Simulator. The Company is in the early stages of developing an insulin pump that is designed to adhere directly to the skin and administer insulin without the need for tubing, commonly known in the diabetes industry as a patch pump. It is also in the early stages of developing a bihormonal configuration of the iLet.
Employees
422
Date Price Change Volume
26-09-28 US$20.52 -4.60% 1,760,463
26-09-25 US$21.51 -1.15% 926,012
26-09-24 US$21.76 -1.94% 906,850
26-09-23 US$22.19 -2.72% 1,396,330
26-09-22 US$22.81 +3.49% 999,585
Trader
Investor
-
Global
-
Quality
-
ESG MSCI
-
Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
13
Last Close Price
20.52USD
Average target price
23.28USD
Spread / Average Target
+13.47%

Quarterly revenue - Rate of surprise

  1. Stock Market
  2. Stocks
  3. BBNX Stock